Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims - Moderna (NASDAQ:MRNA)

Pfizer Inc PFE and its partner, BioNTech SE BNTX, said that they developed their vaccine independently, refuting Moderna Inc's MRNA patent claims.
In August, Moderna filed patent infringement lawsuits saying Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology critical in creating Moderna's mRNA COVID-19 vaccine.
Pfizer called Moderna's lawsuit "revisionist history" and argued its patents "far exceed its actual contributions to the field."
A Pfizer spokesperson said the company and BioNTech are confident in their intellectual property and will "vigorously defend" against Moderna's claims.
Related: Moderna Shares Deep Dive After Lower COVID-19 Vaccine Sales Weigh On Q3 Sales, Profits.
In its lawsuit, Moderna asked for an undisclosed amount of money damages from Pfizer COVID-19 vaccines sold since March.
The companies argued that Moderna ignored the contributions of their scientists to foundational mRNA technology, as well as those of researchers at the U.S. government's National Institutes of Health.
Alnylam Pharmaceuticals Inc ALNY and Arbutus Biopharma Corporation ABUS have lawsuits against Moderna regarding its COVID-19 vaccine.
Price Action: MRNA shares are down 0.75% at $174.61 during the premarket session on the last check Tuesday.